Company news

Rhythm Pharmaceuticals, Inc. news in 2023

Rhythm Pharmaceuticals, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Rhythm Pharmaceuticals Sponsors Second Annual International Meeting on Pathway-Related Obesity: Vision & Evidence (IMPROVE) 2023

December 12, 2023

Rhythm Pharmaceuticals Announces Updates on MC4R Pathway Programs at R&D Event

December 5, 2023

Rhythm Pharmaceuticals Reports Third Quarter 2023 Financial Results and Business Update

November 6, 2023

Rhythm Pharmaceuticals Receives Positive CADTH Reimbursement Recommendation for IMCIVREE® (setmelanotide)

November 1, 2023

Rhythm Pharmaceuticals to Report Third Quarter 2023 Financial Results on Tuesday, November 7, 2023

October 24, 2023

Rhythm Pharmaceuticals Presents Data from its Long-term Extension Study of Setmelanotide Showing Sustained and Deepened BMI Reduction in Patients with Hypothalamic Obesity at One Year at ObesityWeek® 2023

October 16, 2023

Rhythm Pharmaceuticals Announces Six Abstracts to be Presented at The Obesity Society’s Annual Meeting at ObesityWeek ®

October 9, 2023

Rhythm Pharmaceuticals Presents New Data at ESPE 2023

September 21, 2023

Rhythm Pharmaceuticals Receives Orphan Drug Designation from European Medicines Agency for Setmelanotide for Treatment of Acquired Hypothalamic Obesity

September 18, 2023

Rhythm Pharmaceuticals Announces Update to September Conference Participation

September 7, 2023

Rhythm Pharmaceuticals Announces New ICD-10 Diagnosis Code Established for Bardet-Biedl Syndrome

September 5, 2023

Rhythm Pharmaceuticals to Present at Investor Conferences in September

August 27, 2023

Rhythm Pharmaceuticals Announces Pre-Marketing Early Access Authorization for Setmelanotide for Use in Patients with Hypothalamic Obesity in France

August 6, 2023

Rhythm Pharmaceuticals Reports Second Quarter 2023 Financial Results and Business Update

July 31, 2023

Rhythm Pharmaceuticals Announces Two Publications Detailing Burden of Hyperphagia and Obesity on Patients and Caregivers Living with Bardet-Biedl Syndrome

July 18, 2023

Rhythm Pharmaceuticals to Report Second Quarter 2023 Financial Results on Tuesday, August 1, 2023

July 16, 2023

Rhythm Pharmaceuticals Presents Data Demonstrating BMI Reduction in Patients with Hypothalamic Obesity Treated with Setmelanotide over Six Months at ENDO 2023

June 16, 2023

Rhythm Pharmaceuticals to Present at Goldman Sachs 44th Annual Global Healthcare Conference

June 6, 2023

Rhythm Pharmaceuticals and Genpharm Announce Collaboration to Provide IMCIVREE® (setmelanotide) to Patients in Gulf Cooperation Council Countries

May 21, 2023

Rhythm Pharmaceuticals Announces Health Canada Approval of IMCIVREE® Setmelanotide Injection for Weight Management in Bardet-Biedl Syndrome or Genetically-confirmed Biallelic POMC, PCSK1, or LEPR Deficiency

May 7, 2023

Rhythm Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Update

May 1, 2023

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Germany for the Treatment of Obesity and Control of Hunger in Bardet-Biedl Syndrome

April 23, 2023

Rhythm Pharmaceuticals to Report First Quarter 2023 Financial Results on Tuesday, May 2, 2023

April 17, 2023

Rhythm Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference

April 9, 2023

Rhythm Pharmaceuticals Announces Publication of Bardet-Biedl Syndrome Patient and Caregiver Perspectives of Hunger and Quality of Life with Setmelanotide

March 26, 2023

Rhythm Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Financial Results

February 28, 2023

Rhythm Pharmaceuticals Announces Acquisition of Xinvento B.V. and Portfolio of Investigational Therapeutics

February 26, 2023

Rhythm Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Wednesday, March 1, 2023

February 20, 2023

Rhythm Pharmaceuticals Announces Publication of Analysis of Quality of Life Improvements from Phase 3 Clinical Trial in Bardet-Biedl Syndrome

January 22, 2023

Calls in 2023

Decks in 2023